Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) had its price objective reduced by The Goldman Sachs Group from $48.00 to $43.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. The Goldman Sachs Group's price objective points to a potential upside of 251.74% from the stock's current price.
A number of other equities research analysts have also commented on DAWN. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. Needham & Company LLC reissued a "buy" rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, January 13th. TD Cowen raised shares of Day One Biopharmaceuticals to a "strong-buy" rating in a research report on Monday, November 4th. Finally, Bank of America dropped their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $35.71.
Check Out Our Latest Stock Analysis on Day One Biopharmaceuticals
Day One Biopharmaceuticals Stock Up 0.8 %
Shares of DAWN traded up $0.10 during mid-day trading on Monday, reaching $12.23. The company's stock had a trading volume of 503,090 shares, compared to its average volume of 1,021,770. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -11.87 and a beta of -1.46. The business has a fifty day moving average of $12.52 and a 200 day moving average of $13.57. Day One Biopharmaceuticals has a 1 year low of $11.13 and a 1 year high of $18.07.
Insider Activity at Day One Biopharmaceuticals
In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now directly owns 1,034,015 shares of the company's stock, valued at $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 8.40% of the company's stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new stake in Day One Biopharmaceuticals during the fourth quarter worth approximately $31,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock worth $51,000 after buying an additional 1,002 shares during the last quarter. Quest Partners LLC boosted its holdings in shares of Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock worth $108,000 after buying an additional 7,668 shares during the period. E Fund Management Co. Ltd. acquired a new position in Day One Biopharmaceuticals in the 4th quarter valued at $143,000. Finally, KLP Kapitalforvaltning AS bought a new position in Day One Biopharmaceuticals in the 4th quarter worth $150,000. 87.95% of the stock is owned by institutional investors.
About Day One Biopharmaceuticals
(
Get Free Report)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.
Featured Articles
Before you consider Day One Biopharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.
While Day One Biopharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
